Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

Journal of Clinical Investigation

Volumn 97, Issue 11, 1996, Pages 2408-2416

  Berthou, Laurence ^a   Duverger, Nicolas ^a   Emmanuel, Florence ^a   Langouët, Sophie ^c   Auwerx, Johan ^b   Guillouzo, André ^c   Fruchart, Jean Charles ^b   Rubin, Edward ^d   Denèfle, Patrice ^a   Staels, Bart ^b   Branellec, Didier ^a  

^a SANOFI   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atherosclerosis; gene regulation; HDL cholesterol; hypolipidemic drugs; peroxisome proliferation

Indexed keywords

ACYL COENZYME A OXIDASE; APOLIPOPROTEIN A1; CELL NUCLEUS RECEPTOR; DNA FRAGMENT; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PEROXISOME PROLIFERATOR;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEEDING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; LIVER CELL CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

EID: 8944252340     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118687     Document Type: Article

References (68)

1. Puchois, P., A. Kandoussi, J.L. Fourrier, M. Bertrand, E. Koren, and J.C. Fruchart. 1987. Apolipoprotein A-I containing lipoproteins in coronary heart disease. Atherosclerosis. 68:35-40.
2. Fruchart, J.C., G. Ailhaud, and J.M. Bard. 1993. Heterogeneity of high density lipoprotein particles. Circulation. 87:22-27.
3. Forte, T.M., and M.R. McCall. 1994. The role of apolipoprotein A-I-containing lipoproteins in atherosclerosis. Curr. Opin. Lipidol. 5:354-364.
4. Rubin, E.M., R.M. Krauss, E.A. Spangler, J.G. Verstuyft, and S.M. Clift. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al. Nature (Lond.). 353:265-267.
5. Sirtori, C.R., and G. Franceschini. 1988. Effects of fibrates on serum lipids and atherosclerosis. Pharmacol. Ther. 37:167-191.
6. Balfour, J.A., D. McTavish, and R.C. Heel. 1990. Fenofibrate, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs. 40:260-290.
7. Staels, B., N. Vu-Dac, V.A. Kosykh, R. Saladin, J.C. Fruchart, J. Dallongeville, and J. Auwerx. 1995. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J. Clin. Invest. 95:705-712.
8. Petit, D., M.T. Bonnefis, C. Rey, and R. Infante. 1988. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hypercholesterolemic rats. Atherosclerosis. 74:215-225.
9. Goldberg, A.P., D.M. Applebaum-Bowden, E.L. Bierman, W.R Hazzard, L.B. Haas, D.J. Sherrard, J.D. Brunzell, J.K. Huttunen, C. Ehnholm, and E.A. Nikkilä. 1979. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N. Engl. J. Med. 301:1073-1076.
10. Staels, B., and J. Auwerx. 1992. Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and α-fetoprotein as models. Development. 115:1035-1043.
11. Lock, E.A., A.M. Michell, and C.R. Elcombe. 1989. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu. Rev. Pharmacol. Toxicol. 29:145-163.
12. Blaauboer, B.J., C.W.M. van Holstein, R. Bleumink, W.C. Mennes, F.N.A.M. van Pelt, S.H. Yap, J.F. van Pelt, A.A.J. van Iersel, A. Timmerman, and B.P. Schmid. 1990. The effect of beclobric acid and clofibric acid on peroxisomal β-oxidation and peroxisome proliferation in primary cultures rat, monkey and human hepatocytes. Biochem. Pharmacol. 40:521-528.
13. Reddy, J.K., S.K. Goel, M.R. Nemali, J.J. Carrino, T.G. Laffler, M.K. Reddy, S.J. Sperbeck, T. Osumi, T. Hashimoto, N.D. Lalwani, and M.S. Rao. 1986. Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxy-acyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proc. Natl. Acad. Sci. USA. 83:1747-1751.
14. Lazarow, P., and C. de Duve. 1976. A fatty acyl-CoA oxidizing system in rat liver peroxisomes: enhancement by clofibrate, a hypolipidemic drug. Proc. Natl. Acad. Sci. USA. 73:2042-2046.
15. Kozuka, H., J. Yamada, S. Horie, T. Watanabe, T. Suga, and T. Ikeda. 1991. Characteristics of induction of peroxisomal fatty acid oxidation-related enzymes in rat liver by drugs. Biochem. Pharmacol. 41:617-623.
16. Milton, M.N., C.R. Elcombe, and G.G. Gibson. 1990. On the mechanism of induction of microsomal cytochrome P450IVA1 and peroxisome proliferation in rat liver by clofibrate. Biochem. Pharmacol. 40:2727-2732.
17. Tomaszewski, K.E., S.W. Heindel, W.L. Jenkins, and R.L. Melnick. 1990. Induction of peroxisomal acyl CoA oxidase activity and lipid peroxidation in primary rat hepatocyte cultures. Toxicology. 65:49-60.
18. Reddy, J.K., D.L. Azarnoff, and C.E. Hignite. 1980. Hypolipidaemic hepatic peroxisome proliferators from a new class of chemical carcinogens. Nature (Lond.). 283:397-398.
19. Isseman, I., and S. Green. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (Lond.). 347:645-650.
20. Tugwood, J.D., I. Issemann, R.G. Anderson, K.R Bundell, W.L. McPheat, and S. Green. 1992. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO. (Eur. Mol. Biol. Organ.) J. 11:433-439.
21. Dreyer, C., G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli. 1992. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 68:879-887.
22. Auwerx, J. 1992. Regulation of gene expression by fatty acids and fibric acid derivatives: an integrative role for peroxisome proliferator activated receptors. Horm. Res. 38:269-277.
23. Keller, H., C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, and W. Wahli. 1993. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA. 90:2160-2164.
24. Staels, B., A. van Tol, T. Andreu, and J. Auwerx. 1992. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler. Thromb. 12:286-294.
25. Berthou, L., R. Saladin, D. Branellec, P. Calder, J.C. Fruchart, P. Denefle, J. Auwerx, and B. Staels. 1995. Regulation of rat liver apolipoprotein A-I and A-II gene expression by fibrates and dietary fatly acids. Eur. J. Biochem. 232:179-187.
26. Malmendier, C.L., and C. Delecroix. 1985. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis. 55:161-169.
27. Bard, J.M., H.J. Parra, R. Camare, G. Luc, O. Ziegler, C. Dachet, E. Brueckert, P. Douste-Blazy, P. Drouin, B. Jacotot, J.L. De Gennes, U. Keller, and J.C. Fruchart. 1992. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism. 41:498-503.
28. Manninen, V. 1983. Clinical results with gemfibrozil and background to the Helsinki Heart Study. Am. J. Cardiol. 52:35B-38B.
29. Gnasso, A., B. Lehner, W. Haberbosch, O. Leiss, K. von Bergmann, and J. Augustin. 1986. Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects. Metabolism. 35:387-393.
30. 3. J. Biol. Chem. 264:6488-6494.
31. Rubin, E.D., B.Y. Ishida, S.M. Clift, and R.M. Krauss. 1991. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc. Natl. Acad Sci. USA. 88:434-438.
32. Gugen-Guillouzo, C., and A. Guillouzo. 1986. Methods for preparation of adult and fetal hepatocyles. In Isolated and Cultured Hepatocytes (Les edition INSERM and John Libbey, Euro text.) A. Guillouzo and C. Gugen-Guillouzo, editors. Les Editions ISERM and John Libbey Euro Text. Paris. 1-12.
33. Fruchart J.C., C. Fievet, and P. Puchois. 1985. Apolipoproteins. In Methods of Enzymatic Analysis. H.U. Bergmeyer, editor. Academic Press, New York. 3:126-138.
34. Voller, A., D.E. Bidwell, and A. Bartlett. 1976. Enzyme immunoassays in diagnostic medicine. Theory and practice. Bull. W. H. O. 53:55-65.
35. Chomczynski, P., and N. Sacchi. 1987. Single step method for RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
36. Staels, B., J. Auwerx, L. Chan, A. van Tol, M. Rosseneu, and G. Verhoeven. 1989. Influence of development, oestrogens and food intake on apolipoprotein A-I, A-II and E mRNA in the rat liver and intestine. J. Lipid. Res. 30:1137-1145.
37. Breslow, J.L., D. Ross, J. McPherson, H. Williams, A.L. Nussbaum, S.K. Karathanasis, and V.I. Zannis. 1982. Isolation and characterization of cDNA clones for human apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 79:6861-6865.
38. Osumi, T., H. Ozasa, and T. Hashimoto. 1984. Molecular cloning of cDNA for rat acyl-CoA oxidase. J. Biol. Chem. 259:2031-2034.
39. Uzan, G., M. Frain, I. Park, C. Besmond, G. Maessen, J.S. Trepat, M. Zakin, and A. Kahn. 1984. Molecular cloning and sequence analysis of cDNA for human transferrin. Biochem. Biophys. Res. Commun. 119:273-281.
40. Nevins, J.R. 1987. Isolation and analysis of nuclear RNA. Methods Enzymol. 152:234-241.
41. Olivier, P., M.O. Plancke, D. Marzin, V. Clavey, J. Sauzieres, and J.C. Fruchart. 1988. Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. Atherosclerosis. 70:107-114.
42. Lee, S.T., T. Pineau, J. Drago, E.J. Lee, J.W. Owens, D.L. Kroetz, P.M. Fernandez-Salguero, H. Westphal, and K.J. Gonzalez. 1995. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15:3012-3022.
43. Vu-Dac, N., K. Schoonjans, V. Kosykh, J. Dallongeville, J.C. Fruchart, B. Staels, and J. Auwerx. 1995. Fibrates increase human apolipoprotein A-II expression through activation of peroxisome proliferator-activated receptor. J. Clin. Invest. 96:741-750.
44. Schultz, J.R., J.G. Verstuyft, E.L. Gong, A.V. Nichols, and E.M. Rubin. 1993. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature (Lond.). 365:762-764.
45. Stoltzfus, L., and E.M. Rubin. 1993. Atherosclerosis. Insights from the study of transgenic and gene-targeted mice. Trends Cardiovasc. Med. 3:130-134.
46. Breslow, J.L. 1993. Transgenic mouse models of lipoprotein metabolism and atherosclerosis. Proc. Natl. Acad. Sci. USA. 90:8314-8318.
47. Breslow, J.L. 1994. Lipoprotein metabolism and atherosclerosis susceptibility in transgenic mice. Curr. Opin. Lipidol. 5:175-184.
48. Liu, A.C., R.M. Lawn, J.G. Verstuyft, and E.M. Rubin. 1994. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein (a) in transgenic mice. J. Lipid. Res. 35:2263-2267.
49. Paszty, C., N. Maeda, J. Verstuyft, and E.M. Rubin 1994. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94:899-903.
50. Plump, A.S., C.J. Scott, and J.L. Breslow. 1994. Human apolipoprotein A-I gene expression increase high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 91:9607-9611.
51. Widom, R.L., J.A.A. Ladias, S. Kouidou, and S.K. Karathanasis. 1991. Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells. Mol. Cell. Biol. 11:677-687.
52. Vu-Dac, N., K. Schoonjans, B. Laine, J.C. Fruchart, J. Auwerx, and B. Staels. 1994. Negative regulation of the human apolipoprotein AI promoter by fibrates can be attenuated by the interaction of the peroxisome-proliferator-activated receptor with its response element. J. Biol. Chem. 269:31012-31018.
53. Papazafiri, P., K. Ogami, D.P. Ramji, A. Nicosia, P. Monaci, C. Cladaras, and V.I. Zannis. 1991. Promoter elements and factors involved in hepatic transcription of the human apo A-I gene positive and negative regulators bind to overlapping site. J. Biol. Chem. 5790-5797.
54. Harnish, D., S. Malik, and S.K. Karathanasis. 1994. Activation of apolipoprotein A-I gene transcription by the liver-enriched factor HNF-3. J. Biol. Chem. 269:28220-28226.
55. Chan, J., H. Nakabayashi, and N.C.W. Wong. 1993. HNF-4 increases activity of the rat apo A-I gene. Nucleic Acids Res. 21:1205-1211.
56. Rottman, J.N., R.L. Widom, B. Nadal-Ginard, V. Mahdavi, and S.K. Karathanasis. 1991. A retinoic acid-responsive element in the apolipoprotein AI gene distinguishes between two different retinoic acid response pathways. Mol. Cell. Biol. 11:3814-3820.
57. Ladias, J.A.A., and S.K. Karathanasis. 1991. Regulation of the apolipoprotein AI gene by ARP-1, a novel member of the steroid receptor superfamily. Science (Wash. DC). 251:561-565.
58. Ge, R., M. Rhee, S. Malik, and S.K. Karathanasis. 1994. Transcriptional repression of apolipoprotein AI gene expression by orphan receptor ARP-1. J. Biol. Chem. 269:13185-13192.
59. Hayek, T., Y. Ito, N. Azrolan, R.B. Verdery, K. Aalto-Setälä, A. Walsh, and J.L. Breslow. 1993. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (apo) A-I. J. Clin. Invest. 91:1665-1671.
60. Hayek, T., T. Chajek-Shaul, A. Walsh, N. Azrolan, and J.L. Breslow. 1991. Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice. Arterioscler. Thromb. 11:1295-1302.
61. Hahn, S.E., and D.M. Goldberg. 1992. Modulation of lipoprotein production in HepG2 cells by fenofibrate and clofibrate. Biochem. Pharmacol. 43: 625-633.
62. Osumi, T., J.K. Wen, and T. Hashimoto. 1991. Two cis-acting regulatory elements in the peroxisome proliferator-responsive element enhancer region of rat acyl-CoA oxidase gene. Biochem. Biophys. Res. Commun. 175:866-871.
63. Klausing, K., R. Straney, and M. Briggs. 1995. The human apolipoprotein A1 promoter contains a novel PPRE. Circulation. 92:I-291. (Abstr.)
64. Hertz, R., J. Bishara-Shieban, and J. Bar-Tana. 1995. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J. Biol. Chem. 270:13470-13475.
65. Krause, B.R., and R.S Newton. 1985. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats. J. Lipid. Res. 26:940-949.
66. Krause, B.R., and R.S Newton. 1986 Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipids regulators in cholesterol-fed rats. Atherosclerosis. 59:95-98.
67. Gould, A.L., J.E. Rossouw, N.C. Santanello, J.F. Heyse, and C.D. Furberg. 1995. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation. 61:2274-2282.
68. Duverger, N., F. Emmanuel, C. Viglietta, A. Tailleux, P. Benoit, F. Attenot, S. Cuiné, C. Fievet, B. Laine, et al. 1994. Human apolipoprotein A-I gene transfer in the rabbit: incidence on atherogenesis. Circulation. 90:I-240. (Abstr.)